References
- Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol. [Internet]. 1999 [cited 2018 Dec 13];141:398–405. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10583042
- Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. [Internet]. 2014 [cited 2018 Dec 13];15:217–230. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24848508
- Gilhar A, Etzioni A, Paus R. Alopecia Areata. N Engl J Med. [Internet]. 2012 [cited 2018 Nov 3];366:1515–1525. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22512484
- Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. [Internet]. 2018 [cited 2018 Nov 3];78:1–12. Available from: https://linkinghub.elsevier.com/retrieve/pii/S019096221731873X
- Messenger AG, McKillop J, Farrant P, et al. British association of dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. [Internet]. 2012 [cited 2018 Nov 3];166:916–926. Available from: http://doi.wiley.com/10.1111/j.1365-2133.2012.10955.x
- Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. [Internet]. 2017 [cited 2018 Nov 3];76:736–744. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0190962216311884
- O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. [Internet]. 2015 [cited 2018 Nov 3];66:311–328. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25587654
- Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. [Internet]. 2014 [cited 2018 Nov 3];20:1043–1049. Available from: http://www.nature.com/articles/nm.3645
- Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. [Internet]. 2017 [cited 2018 Nov 3];34:1594–1609. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28646393
- Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. [Internet]. 2016 [cited 2018 Nov 3];1:e89776. Available from: https://insight.jci.org/articles/view/89776
- Jabbari A, Sansaricq F, Cerise J, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol. [Internet]. 2018 [cited 2018 Nov 3];138:1539–1545. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29452121
- Liu LY, Craiglow BG, Dai F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. [Internet]. 2017 [cited 2018 Nov 3];76:22–28. Available from: https://www-sciencedirect-com.access.library.miami.edu/science/article/pii/S0190962216307630?via%3Dihub
- Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. [Internet]. 2017 [cited 2018 Nov 3];76:29–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27816292
- Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. [Internet]. 2016 [cited 2018 Nov 3];1:e89790. Available from: https://insight.jci.org/articles/view/89790
- Ramot Y, Zlotogorski A. Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient. Ski Appendage Disord. [Internet]. 2018 [cited 2018 Nov 3];4:122–124. Available from: https://www.karger.com/Article/FullText/479722
- Iorizzo M, Tosti A. Emerging drugs for alopecia areata: JAK inhibitors. Expert Opin Emerg Drugs. [Internet]. 2018 [cited 2018 Nov 3];23:77–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29466675
- Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. [Internet]. 2015 [cited 2018 Nov 3];2:351–355. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352396415000638
- Cinats A, Heck E, Robertson L. Janus kinase inhibitors: a review of their emerging applications in dermatology. Skin Therapy Lett. [Internet]. 2018 [cited 2018 Nov 2];23:5–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29772037
- Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. [Internet]. 2016 [cited 2018 Nov 2];174:1266–1276. Available from: http://doi.wiley.com/10.1111/bjd.14403
- Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. [Internet]. 2014 [cited 2018 Nov 3];41:837–852. Available from: http://www.jrheum.org/cgi/doi/10.3899/jrheum.130683
- He Y, Wong AY, Chan EW, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. [Internet]. 2013 [cited 2018 Nov 3];14:298. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24139404
- Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. (Hoboken, NJ) [Internet]. 2014 [cited 2018 Nov 3];66:2924–2937. Available from: http://doi.wiley.com/10.1002/art.38779
- Papp KA, Krueger JG, Feldman SR, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. [Internet]. 2016 [cited 2018 Nov 3];74:841–850. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0190962216000268
- Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. [Internet]. 2015 [cited 2018 Nov 3];100:479–488. Available from: http://www.haematologica.org/cgi/doi/10.3324/haematol.2014.115840
- Arana Yi C, Tam CS, Verstovsek S. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Futur Oncol. [Internet]. 2015 [cited 2018 Nov 3];11:719–733. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25757677
- Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. [Internet]. 2016 [cited 2018 Nov 3];75:831–841. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25902789
- Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. [Internet]. 2016 [cited 2018 Nov 3];18:34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26818974
- Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. [Internet]. 2015 [cited 2018 Nov 3];1:e1500973. Available from: http://advances.sciencemag.org/cgi/doi/10.1126/sciadv.1500973
- Ly L, Craiglow BG, Ba K. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. J Am Acad Dermatol. [Internet]. 2018 [cited 2018 Nov 3];78:403–404.e1. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0190962217326014
- Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol. [Internet]. 2016 [cited 2018 Nov 3];152:490. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26649829
- Craiglow BG. Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes. JAAD Case Rep. [Internet]. 2018 [cited 2018 Dec 16];4:988–989. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30417059
- Bayart CB, DeNiro KL, Brichta L, et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. [Internet]. 2017 [cited 2018 Nov 3];77:167–170. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28619556
- Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study. Int J Dermatol. 2018;57:1464–1470. [Internet]. [cited 2018 Dec 31]; Available from: http://doi.wiley.com/10.1111/ijd.14192
- LEO Pharma. Clinical trial report synopsis - efficacy of twice daily applications of LEO 124249 ointment 30mg/g for 12 weeks to subjects with alopecia areata [Internet]. 2017 [cited 2018 Nov 5]. Available from: http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports/Clinical-trial-search/Alopecia-areata.aspx.
- Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol. [Internet]. 1983 [cited 2018 Nov 3];63:49–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6191489
- Lamb RC, Young D, Holmes S. Retrospective review of diphencyprone in the treatment of alopecia areata. Clin Exp Dermatol. Internet]. 2016 [cited 2018 Nov 2];41:352–358. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26620737
- Katikaneni R, Seymour AW, Gulati R, et al. Therapy for alopecia areata in mice by stimulating the hair cycle with parathyroid hormone agonists linked to a collagen-binding domain. J Investig Dermatology Symp Proc. Internet]. 2015 [cited 2018 Nov 3];17:13–15. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1087002416300326
- Venten I, Hess N, Hirschmüller A, et al. Treatment of therapy-resistant Alopecia areata with fumaric acid esters. Eur J Med Res. Internet]. 2006 [cited 2018 Nov 2];11:300–305. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16899425
- Niculescu L, Heppt MV, Varga R, et al. Retrospective analysis of the application of fumaric acid esters in 13 patients with alopecia areata. Eur J Dermatol. [Internet]. 2018 [cited 2018 Nov 2];28:376–377. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30105993
- Ha B, Ed D. Abatacept: a review in rheumatoid arthritis. Drugs. Internet]. 2017 [cited 2018 Nov 2];77:1221–1233. Available from: http://link.springer.com/10.1007/s40265-017-0775-4
- Ursini F, Russo E, De Giorgio R, et al. Current treatment options for psoriatic arthritis: spotlight on abatacept. Ther Clin Risk Manag. [Internet]. 2018 [cited 2018 Nov 2];14:1053–1059. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29922065
- Magdaleno-Tapial J, Valenzuela-Oñate C, Sánchez-Carazo JL, et al. 2018. Improvement of alopecia areata with apremilast. Australas J Dermatol. [Internet]. [cited 2018 Nov 3]; Available from: http://doi.wiley.com/10.1111/ajd.12934
- Keren A, Shemer A, Ullmann Y, et al. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J Dermatol Sci. [Internet]. 2015 [cited 2018 Nov 5];77:74–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25530115
- Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. J Am Acad Dermatol. Internet]. 2017 [cited 2018 Nov 3];77:773–774. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0190962217317826
- Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. [Internet]. 2014 [cited 2018 Nov 3];371:130–139. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25006719
- Penzi LR, Yasuda M, Manatis-Lornell A, et al. Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol. [Internet]. 2018 [cited 2018 Nov 3]; Available from: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2018.2976
- Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. [Internet]. 2018 [cited 2018 Nov 3];4:143–144. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352512617302989
- Iftikhar IH, Schimmel M, Bender W, et al. Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung. [Internet]. 2018 [cited 2018 Nov 2];196:517–530. Available from: http://link.springer.com/10.1007/s00408-018-0151-5
- Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb. J Allergy Clin Immunol. [Internet]. 2018 [cited 2018 Nov 2]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/29906525
- Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. [Internet]. 2011 [cited 2018 Nov 3];9:S1–S57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21980982
- Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol. [Internet]. 1992 [cited 2018 Nov 3];127:239–246. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1390168
- Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. [Internet]. 2010 [cited 2018 Nov 3];4:349–358. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20463804
- Duke University. Topical bimatoprost effect on androgen dependent hair follicles. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2018 Nov 3]. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT01325350NLMIdentifier:NCT01325350
- Allergan. Safety and efficacy study of bimatoprost in the treatment of women with female pattern hair loss. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2018 Nov 3]. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01325350NLMIdentifier:NCT01325350
- Allergan. Safety and efficacy study of bimatoprost in the treatment of men with androgenic alopecia. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2018 Nov 3]. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01325337NLMIdentifier:NCT01325337
- Allergan. A safety and efficacy study of bimatoprost in men with androgenic alopecia (AGA). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Nov 3]. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01904721NLMIdentifier:NCT01904721
- Blume-Peytavi U, Lönnfors S, Hillmann K, et al. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. [Internet]. 2012 [cited 2018 Nov 3];66:794–800. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0190962211006013
- Talavera-Adame D, Newman D, Newman N. Conventional and novel stem cell based therapies for androgenic alopecia. Stem Cells Cloning. [Internet]. 2017 [cited 2018 Nov 3];10:11–19. Available from: https://www.dovepress.com/conventional-and-novel-stem-cell-based-therapies-for-androgenic-alopec-peer-reviewed-article-SCCAA
- Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. [Internet]. 2012 [cited 2018 Nov 3];4:126ra34. Available from: http://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.3003122
- Ratner P, Andrews CP, Hampel FC, et al. Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from phase 2 and phase 3 randomized, double-blind, placebo- and active-referenced studies. Allergy, Asthma Clin Immunol. [Internet]. 2017 [cited 2018 Nov 2];13:18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28392807
- Premanand A, Reena Rajkumari B. Androgen modulation of Wnt/β-catenin signaling in androgenetic alopecia. Arch Dermatol Res. [Internet]. 2018 [cited 2018 Nov 3];310:391–399. Available from: http://link.springer.com/10.1007/s00403-018-1826-8
- Yazici Y, Swearingen CJ, Simsek I, et al. Safety, tolerability and efficacy of a topical treatment (sm04554) for androgenetic alopecia (aga): results from a phase 2 trial. Poster session presented at: American Academy of Dermatology (AAD); 2016 March 04–08; Washington, (DC).
- Seykora J, Simsek I, DiFrancesco A, et al. Safety and biopsy outcomes of a topical treatment (sm04554) for male androgenetic alopecia (aga): results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial. Poster session presented at: American Academy of Dermatology (AAD); 2017 March 03–07; Orlando, (FL).
- Samumed. Monthly newsletter. 2018 Aug [Internet]. [cited 2018 Nov 2]. Available from: https://www.samumed.com/medium/image/monthly-newsletter-2018-7_387/view.aspx
- Cassiopea. Creating innovation in dermatology. Presented at: jefferies Global Health Care Conference; 2016 June 9; New York, (NY); Available from: http://www.cassiopea.com/~/media/Files/C/Cassiopea/presentations/Jefferies_GHCC_Jun2016.pdf
- Cassiopea. Breezula [Internet]. [cited 2018 Nov 2]. Available from: http://www.cassiopea.com/activities/product-pipeline/breezula.aspx
- Caserini M, Radicioni M, Leuratti C, et al. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. [Internet]. 2016 [cited 2018 Nov 3];54:19–27. Available from: http://www.dustri.com/article_response_page.html?artId=13950&doi=10.5414/CP202467&L=0
- Suchonwanit P, Srisuwanwattana P, Chalermroj N, et al. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. [Internet]. 2018 [cited 2018 Dec 13];32:2257–2263. Available from: http://doi.wiley.com/10.1111/jdv.15171
- van Vollenhoven R, Helt C, Arora V, et al. Safety and efficacy of baricitinib in patients receiving conventional synthetic disease-modifying antirheumatic drugs or corticosteroids. Rheumatol Ther. [Internet]. 2018 [cited 2019 Jan 4];5:525–536. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30357613
- The Belgravia Center. Pfizer ‘Breakthrough’ JAK inhibitor for severe alopecia areata [Internet]. 2018 [cited 2019 Jan 1]. Available from: https://www.belgraviacentre.com/blog/pfizer-breakthrough-jak-inhibitor-for-severe-alopecia-areata/
- Chastek B, White J, Van Voorhis D, et al. A retrospective cohort study comparing utilization and costs of biologic therapies and jak inhibitor therapy across four common inflammatory indications in adult US managed care patients. Adv Ther. [Internet]. 2016 [cited 2018 Dec 31];33:626–642. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26970958
- Hosking A-M, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol. [Internet]. 2018 [cited 2018 Dec 31];79:535–544. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29673776
- Rebello D, Wang E, Yen E, et al. Hair growth in two alopecia patients after fecal microbiota transplant. ACG Case Reports J. [Internet]. 2017 [cited 2019 Jan 4];4:e107. Available from: http://acgcasereports.gi.org/hair-growth-in-two-alopecia-patients-after-fecal-microbiota-transplant/
- Dizen-Namdar N, Emel Kocak F, Kidir M, et al. Evaluation of serum paraoxonase, arylesterase, prolidase activities and oxidative stress in patients with alopecia areata. Skin Pharmacol Physiol. [Internet]. 2018 [cited 2019 Jan 4];32:59–64. Available from: https://www.karger.com/Article/FullText/494690
- Owczarczyk-Saczonek A, Krajewska-Włodarczyk M, Kruszewska A, et al. Therapeutic potential of stem cells in follicle regeneration. Stem Cells Int. [Internet]. 2018 [cited 2019 Jan 1];2018:1049641. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30154860